Investor Presentaiton slide image

Investor Presentaiton

Key challenge for (bio-)pharmaceutical products Key challenge: Medical safety Medication safety is key and (cross-) contamination unacceptable Key contamination sources: Air particles Input: Raw materials, containers, closures Personnel Products: Injectables Cancer drugs (ADC, Cytotoxics) Cell & gene therapy (Advanced Therapy Medicinal Products (ATMPS)) Hormones: Insulin Medical drugs (Thrombosis, EPO, blood plasma products, botox, etc.) Vaccines: Flu, COVID-19, etc. November 2023 SKAN Group AG Investor Presentation Increased infection risk as their application bypasses many of the human body's natural defenses A STERILE SLE USE E In particular true for: High-value biopharma drugs Risk of significant economic losses if high-value biopharma drugs get contaminated Risk of cross-contamination increases with small batch size of fast-growing personalized medicine 3 SKAN
View entire presentation